Serum Midkine Levels in Systemic Lupus Erythematosus

Overview

Journal Open Access Maced J Med Sci

Specialty General Medicine

Date 2018 Aug 31

PMID 30159050

Citations 2

Authors

Blondina Marpaung

Andi Raga Ginting

Ok Moehad Sjah

Affiliations

Soon will be listed here.

Abstract

Background: Midkine (MK) induces inflammation and could inhibit inducible regulatory T cell differentiation. These reports suggest that MK may play a role in the pathogenesis of autoimmune disease including SLE, but data about MK in SLE patients was still limited, and the role of Midkine in SLE is largely unknown.

Aim: The purpose of this study was to compare serum level MK in SLE patients and control, also analysed the relationship between the serum MK level and disease activity in SLE.

Methods: This cross-sectional study was conducted in Adam Malik Hospital from January-June 2017. Diagnosis of SLE was established according to the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria, and disease activity was assessed using the Mexican Systemic lupus erythematosus disease activity index (MEX-SLEDAI). Subjects with evidence of malignancy and systemic disease (pulmonary, kidney, liver, metabolic disorder, etc.) were excluded. Data analysis was performed using SPSS 22nd version. P < 0.05 was considered statistically significant.

Results: There were 90 subjects and divided into 2 groups: SLE patients group (n=40) and healthy control groups (n = 50). Midkine levels were increased in the serum of SLE patients compared by health control. There was a significant difference in the median serum Midkine levels between SLE patients and healthy control (P < 0.001). Elevated Midkine serum levels were a significant difference between active disease and remission (P = 0.018).

Conclusion: Elevated Midkine serum level could be a marker of SLE disease activity and have a role in the pathogenesis of SLE.

Citing Articles

The role of midkine in health and disease.

Neumaier E, Rothhammer V, Linnerbauer M Front Immunol. 2023; 14:1310094.

PMID: 38098484 PMC: 10720637. DOI: 10.3389/fimmu.2023.1310094.

Human macrophages and monocyte-derived dendritic cells stimulate the proliferation of endothelial cells through midkine production.

Said E, Al-Dughaishi S, Al-Hatmi W, Al-Reesi I, Al-Riyami M, Al-Balushi M PLoS One. 2022; 17(4):e0267662.

PMID: 35476724 PMC: 9045650. DOI: 10.1371/journal.pone.0267662.

References

Krzystek-Korpacka M, Neubauer K, Matusiewicz M . Clinical relevance of circulating midkine in ulcerative colitis. Clin Chem Lab Med. 2009; 47(9):1085-90. DOI: 10.1515/CCLM.2009.248. View

Shindo E, Nanki T, Kusunoki N, Shikano K, Kawazoe M, Sato H . The growth factor midkine may play a pathophysiological role in rheumatoid arthritis. Mod Rheumatol. 2016; 27(1):54-59. DOI: 10.1080/14397595.2016.1179860. View

Wang J, Takeuchi H, Sonobe Y, Jin S, Mizuno T, Miyakawa S . Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A. 2008; 105(10):3915-20. PMC: 2268842. DOI: 10.1073/pnas.0709592105. View

Masuda T, Maeda K, Sato W, Kosugi T, Sato Y, Kojima H . Growth Factor Midkine Promotes T-Cell Activation through Nuclear Factor of Activated T Cells Signaling and Th1 Cell Differentiation in Lupus Nephritis. Am J Pathol. 2017; 187(4):740-751. DOI: 10.1016/j.ajpath.2016.12.006. View

Muramatsu T . Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem. 2002; 132(3):359-71. DOI: 10.1093/oxfordjournals.jbchem.a003231. View

Ohl K, Tenbrock K . Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2014; 45(2):344-55. DOI: 10.1002/eji.201344280. View

Weckbach L, Muramatsu T, Walzog B . Midkine in inflammation. ScientificWorldJournal. 2012; 11:2491-505. PMC: 3253530. DOI: 10.1100/2011/517152. View

Sonobe Y, Li H, Jin S, Kishida S, Kadomatsu K, Takeuchi H . Midkine inhibits inducible regulatory T cell differentiation by suppressing the development of tolerogenic dendritic cells. J Immunol. 2012; 188(6):2602-11. DOI: 10.4049/jimmunol.1102346. View

Ibusuki M, Fujimori H, Yamamoto Y, Ota K, Ueda M, Shinriki S . Midkine in plasma as a novel breast cancer marker. Cancer Sci. 2009; 100(9):1735-9. PMC: 11159736. DOI: 10.1111/j.1349-7006.2009.01233.x. View

10.

Jacob N, Stohl W . Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011; 13(4):228. PMC: 3239336. DOI: 10.1186/ar3349. View

11.

Shaygannejad V, Montazeri S, Jamshidian A, Tahani S, Gharagozloo M, Ashtari F . Correlation of midkine serum level with pro- and anti-inflamatory cytokines in multiple sclerosis. Iran J Immunol. 2014; 11(2):134-8. DOI: IJIv11i2A8. View

12.

Liu Z, Davidson A . Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012; 18(6):871-82. PMC: 3607103. DOI: 10.1038/nm.2752. View

13.

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

14.

Scheinecker C, Bonelli M, Smolen J . Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun. 2010; 35(3):269-75. DOI: 10.1016/j.jaut.2010.06.018. View

15.

Wu G, Yuan H, Pan H, Ye D . Elevated plasma midkine and pleiotrophin levels in patients with systemic lupus erythematosus. Oncotarget. 2016; 8(25):40181-40189. PMC: 5522313. DOI: 10.18632/oncotarget.13658. View

16.

Khanna S, Pal H, Pandey R, Handa R . The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2004; 43(12):1536-40. DOI: 10.1093/rheumatology/keh376. View

17.

Krzystek-Korpacka M, Neubauer K, Matusiewicz M . Circulating midkine in Crohn's disease: clinical implications. Inflamm Bowel Dis. 2009; 16(2):208-15. DOI: 10.1002/ibd.21011. View

18.

Hung Y, Lin Z, Cheng T, Liang C, Kuo T, Kao K . Serum midkine as a prognostic biomarker for patients with hepatocellular carcinoma. Am J Clin Pathol. 2011; 136(4):594-603. DOI: 10.1309/AJCPWT70XOVXSVGE. View